Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lazertinib”

39 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 39 results

Testing effectiveness (Phase 2)UnknownNCT05277701
What this trial is testing

Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations

Who this might be right for
NSCLC
Yonsei University 36
Large-scale testing (Phase 3)Study completedNCT04248829
What this trial is testing

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Who this might be right for
Non-Small Cell Lung Cancer
Yuhan Corporation 393
Large-scale testing (Phase 3)Active Not RecruitingNCT04988295
What this trial is testing

Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 776
Testing effectiveness (Phase 2)Looking for participantsNCT06667076
What this trial is testing

Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 480
Testing effectiveness (Phase 2)Looking for participantsNCT06106802
What this trial is testing

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Who this might be right for
Non-Small Cell Lung Cancer Metastatic
Sehhoon Park 47
Testing effectiveness (Phase 2)Active Not RecruitingNCT06268210
What this trial is testing

Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Yonsei University 160
Testing effectiveness (Phase 2)Looking for participantsNCT07774520
What this trial is testing

Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy

Who this might be right for
Non-small Cell Lung Cancer(NSCLC)EGFR Mutant
Samsung Medical Center 1,173
Early research (Phase 1)Study completedNCT04410094
What this trial is testing

Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants

Who this might be right for
Healthy
Janssen Research & Development, LLC 32
Not applicableUnknownNCT05377788
What this trial is testing

Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaEGFR T790M
Samsung Medical Center 900
Early research (Phase 1)Study completedNCT05112952
What this trial is testing

Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)

Who this might be right for
Hepatic ImpairmentHealthy
Janssen Research & Development, LLC 16
Not applicableUnknownNCT05716672
What this trial is testing

Impact of Lazertinib Dose Modification on Effectiveness and Safety

Who this might be right for
Non-small Cell Lung Cancer
Pusan National University Hospital 200
Testing effectiveness (Phase 2)Study completedNCT04075396
What this trial is testing

Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 29
Large-scale testing (Phase 3)Active Not RecruitingNCT05388669
What this trial is testing

Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Advanced or Metastatic Non-small Cell Lung Cancer
Janssen Research & Development, LLC 418
Testing effectiveness (Phase 2)UnknownNCT05477615
What this trial is testing

Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases

Who this might be right for
Non-small Cell Lung Cancer
Jin Hyoung Kang 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07507188
What this trial is testing

Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)

Who this might be right for
Non Small Cell Lung Cancer
Yonsei University 80
Testing effectiveness (Phase 2)Looking for participantsNCT05469022
What this trial is testing

Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy

Who this might be right for
Non Small Cell Lung Cancer
Konkuk University Medical Center 40
Early research (Phase 1)Study completedNCT05896683
What this trial is testing

Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants

Who this might be right for
Healthy
Janssen Research & Development, LLC 72
Early research (Phase 1)Study completedNCT05162274
What this trial is testing

Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.

Who this might be right for
Healthy Adult Volunteers
Yuhan Corporation 38
Post-approval studies (Phase 4)Not Yet RecruitingNCT07469488
What this trial is testing

A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)VTE (Venous Thromboembolism)Rash Due to Epidermal Growth Factor Receptor Inhibitors+1 more
Shanghai Pulmonary Hospital, Shanghai, China 122
Testing effectiveness (Phase 2)Active Not RecruitingNCT06120140
What this trial is testing

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 305
Next Page